At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,007 enrolled
Drug / intervention
Rapamycin-eluting Stent +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis
In Brief
A Phase 4 clinical trial evaluating Rapamycin-eluting Stent and Zotarolimus-eluting Stent for Coronary Disease. Completed, enrolled 1,007 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of 3 different drug-eluting-stent platforms to reduce coronary artery reblockage after stent implantation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedJun 2006
Study CompletionJul 2007
TodayJul 2026
First PostedJun 1, 2006
Enrollment StartMar 1, 2006
Study CompletionJul 1, 2007
TodayJul 1, 2026
Posted 20.1 years ago
Interventions
Rapamycin-eluting Stentdevice
due to randomization, Cypher stent will be implanted
Zotarolimus-eluting Stentdevice
due to randomization, Endeavor stent will be implanted
Rapamycin-eluting Stentdevice
due to randomization, rapamycin-eluting stent will be implanted